Transaction overview
ClearPoint Neuro (NASDAQ: CLPT), a medical technology company providing precise navigation for neurosurgical procedures and cell and gene therapy delivery, secured financing of up to $110 million from Oberland Capital Management LLC on May 12, 2025. The initial funding at closing was $35 million, comprising both debt and equity components.
Deal structure and financing
The transaction includes a note financing arrangement with an initial funding of $30 million and options for additional financings up to $75 million by December 31, 2026. At the close date, ClearPoint Neuro received $30 million in gross proceeds from the note issuance and $3.5 million from the sale of common stock through a registered direct offering at $12.69 per share. Covington & Burling LLP served as legal advisor to ClearPoint Neuro on the financings, while Sheppard, Mullin, Richter & Hampton LLP advised on the equity component of the transaction. The debt portion was structured under an exemption from U.S. Securities and Exchange Commission (SEC) registration requirements.
Strategic context
Oberland Capital's investment is designed to support ClearPoint Neuro’s growth in both product development and commercialization of neurosurgical navigation systems and cell and gene therapy delivery solutions. The financing will enable the company to expand its product offerings, increase market penetration, and enhance operational capabilities, particularly in anticipation of increased demand for advanced medical therapies. Oberland Capital’s specialized focus on healthcare and structured finance aligns closely with ClearPoint Neuro's strategic objectives, providing a flexible financial framework that can adapt to future growth opportunities.
Regulatory path
This financing arrangement does not require regulatory approval from the U.S. Securities and Exchange Commission or any other governmental body, as it adheres strictly to established securities laws and exemptions applicable in the United States. The transaction involves an exemption under Section 4(a)(2) of the Securities Act for non-registered note issuances and follows a registered direct offering framework that complies with SEC rules.
The financial structure was designed to comply with existing regulatory frameworks, ensuring transparency and adherence to legal requirements governing private placements and equity offerings.